Last reply 2 months ago
Ocrelizumab – Even More +ve Data

Not the worst thing I have read today!

Ocrevus’ Early Use May Lower Need for Walking Aid by 49% Over 6 Years – https://multiplesclerosisnewstoday.com/news-posts/2020/04/28/new-6-year-data-for-genentechs-ocrevus-ocrelizumab-show-earlier-treatment-initiation-nearly-halves-risk-of-needing-walking-aid-in-relapsing-multiple-sclerosis/

Ocrelizumab (Ocrevus) now has a 20% market share in the US! I see why induction therapy – hitting it hard and early – is being increasingly favoured over the tippy-toe up to it with old drugs approach.

The idea about medicating for the prevention/reduction of future disability is really what underpins the induction approach.

Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.

Join Shift.ms to reply to this post.

Become part of the community so you can chat, compare and learn from other MSers.